These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21788997)

  • 1. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia.
    Xiao SF; Xue HB; Li X; Chen C; Li GJ; Yuan CM; Zhang MY
    Neurosci Bull; 2011 Aug; 27(4):258-68. PubMed ID: 21788997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms.
    Xiao S; Xue H; Li G; Yuan C; Li X; Chen C; Wu HZ; Mitchell P; Zhang M
    Aust N Z J Psychiatry; 2012 Feb; 46(2):153-60. PubMed ID: 22311531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
    Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
    Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.
    Akhondzadeh S; Ghayyoumi R; Rezaei F; Salehi B; Modabbernia AH; Maroufi A; Esfandiari GR; Naderi M; Ghebleh F; Tabrizi M; Rezazadeh SA
    Psychopharmacology (Berl); 2011 Feb; 213(4):809-15. PubMed ID: 20949350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.
    Casey DE; Sands EE; Heisterberg J; Yang HM
    Psychopharmacology (Berl); 2008 Oct; 200(3):317-31. PubMed ID: 18597078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.
    Azorin JM; Spiegel R; Remington G; Vanelle JM; Péré JJ; Giguere M; Bourdeix I
    Am J Psychiatry; 2001 Aug; 158(8):1305-13. PubMed ID: 11481167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
    Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
    Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.
    Moazen-Zadeh E; Bayanati S; Ziafat K; Rezaei F; Mesgarpour B; Akhondzadeh S
    J Psychopharmacol; 2020 May; 34(5):506-513. PubMed ID: 32122230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial.
    Ghanizadeh A; Dehbozorgi S; OmraniSigaroodi M; Rezaei Z
    Recent Pat Inflamm Allergy Drug Discov; 2014; 8(3):211-5. PubMed ID: 25353174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis).
    Miyaoka T; Furuya M; Horiguchi J; Wake R; Hashioka S; Tohyama M; Mori N; Minabe Y; Iyo M; Ueno S; Ezoe S; Murotani K; Hoshino S; Seno H
    Psychopharmacology (Berl); 2015 Jan; 232(1):155-64. PubMed ID: 24923986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial.
    Chen ZH; Wang GH; Wang XP; Huo YX; Yang MH; Li L; Mei HB
    Clin Rehabil; 2009 Nov; 23(11):963-72. PubMed ID: 19786416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical observation on effect of modified Daotan Decoction combined with small dose risperidone in treating chronic schizophrenia].
    Liu JL; Ma L; Wang Y
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Mar; 27(3):208-10. PubMed ID: 17432677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
    Schaefer M; Sarkar S; Theophil I; Leopold K; Heinz A; Gallinat J
    Pharmacopsychiatry; 2020 Jan; 53(1):21-29. PubMed ID: 31390660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.